EMEA-001984-PIP03-20
Key facts
| Active substance |
Sparsentan
|
| Therapeutic area |
Uro-nephrology
|
| Decision number |
P/0024/2021
|
| PIP number |
EMEA-001984-PIP03-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of primary IgA nephropathy
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Vifor (International) AG
Email: sparsentan_ra@viforpharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|